GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (OTCPK:ANTCF) » Definitions » Buyback Yield %

ANTCF (Aion Therapeutic) Buyback Yield % : -8.89 (As of Apr. 11, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Aion Therapeutic Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aion Therapeutic's current buyback yield was -8.89%.


Aion Therapeutic Buyback Yield % Historical Data

The historical data trend for Aion Therapeutic's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic Buyback Yield % Chart

Aion Therapeutic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Buyback Yield %
Get a 7-Day Free Trial - -23.35 -55.97 - -16.08

Aion Therapeutic Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.83 -8.80 -6.60 -16.10 -5.93

Competitive Comparison of Aion Therapeutic's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Buyback Yield % falls into.


;
;

Aion Therapeutic Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aion Therapeutic's Buyback Yield for the fiscal year that ended in Apr. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.397) / 2.469294
=-16.08%

Aion Therapeutic's annualized Buyback Yield for the quarter that ended in Oct. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0.322) / 2.8834642
=-11.17%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Aion Therapeutic Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aion Therapeutic Business Description

Traded in Other Exchanges
Address
700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.